Suzhou Ribo Life Science
CompanyChina
Suzhou Ribo Life Science develops one asset, in phase 1 (RBD3133 in obesity). Mostly oligonucleotide acting on lipid and ceramide metabolism and INHBE; based in China.
- 1
- Asset
- Furthest stage
- Phase 1
- 0
- Trials
- 1
- Signal
Pipeline
1siRNA targeting INHBE to regulate metabolic processes.
Phase 1, Oligonucleotide, Lipid and ceramide metabolism, INHBE, obesity
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Signals1
- Similar companies6